atai Life Sciences increased its ownership interest in COMPASS Pathways from 19.4% to 20.8% indicating the potential of COMP360 in mental health care, post the recent COMP360 data in treatment-resistant depression.
Compound Psilocybin
Visit article
Category Press Release
Country Germany
Companies Featured
atai Life Sciencesatai Life Sciences is one of the biggest companies in the psychedelics field. The company aims to be a platform and has nine subsidiary companies working on everything from psilocybin for depression to DMT administration.
COMPASS Pathways
COMPASS Pathways is a publicly listed company (NASDAQ) that is developing psilocybin for treatment-resistant depression (TRD) for which it has completed a successful Phase IIb trial. COMPASS is one of the largest psychedelic companies and has received substantial investment from atai.